Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 25;10(6):632.
doi: 10.3390/antibiotics10060632.

In Silico Prediction and Prioritization of Novel Selective Antimicrobial Drug Targets in Escherichia coli

Affiliations

In Silico Prediction and Prioritization of Novel Selective Antimicrobial Drug Targets in Escherichia coli

Frida Svanberg Frisinger et al. Antibiotics (Basel). .

Abstract

Novel antimicrobials interfering with pathogen-specific targets can minimize the risk of perturbations of the gut microbiota (dysbiosis) during therapy. We employed an in silico approach to identify essential proteins in Escherichia coli that are either absent or have low sequence identity in seven beneficial taxa of the gut microbiota: Faecalibacterium, Prevotella, Ruminococcus,&nbsp;Bacteroides, Lactobacillus, Lachnospiraceae and Bifidobacterium. We identified 36 essential proteins that are present in hyper-virulent E. coli ST131 and have low similarity (bitscore < 50 or identity < 30% and alignment length < 25%) to proteins in mammalian hosts and beneficial taxa. Of these, 35 are also present in Klebsiella pneumoniae. None of the proteins are targets of clinically used antibiotics, and 3D structure is available for 23 of them. Four proteins (LptD, LptE, LolB and BamD) are easily accessible as drug targets due to their location in the outer membrane, especially LptD, which contains extracellular domains. Our results indicate that it may be possible to selectively interfere with essential biological processes in Enterobacteriaceae that are absent or mediated by unrelated proteins in beneficial taxa residing in the gut. The identified targets can be used to discover antimicrobial drugs effective against these opportunistic pathogens with a decreased risk of causing dysbiosis.

Keywords: Escherichia coli; antimicrobial targets; in silico; microbiota.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Flow diagram showing the different steps of the selection procedure used to identify novel selective antimicrobial drug targets against E. coli.
Figure 2
Figure 2
Function and SCL of the identified protein targets. The identified targets are drawn in pink, with surrounding proteins in gray. The proteins drawn are part of various cellular processes, including cell cycle (ZipA, FtsB, FtsL, FtsQ, MukB, MukE and MukF), cell shape (MreD), transport (CydX), outer membrane processes (BamD, SecE, LolA, LolB, LptA, LptD and LptE) and DNA replication (DnaT, PriB and HolD). Other inner membrane proteins are WzyE, YciS, YrfF and SafA, and cytoplasmic proteins are FabA, IraM, TusE, YgfZ and YcaR. Proteins without a determined SCL are not shown: HemD, TrpL, HigA, HipB, PheM, YdfO, YdhL and YqeL.

Similar articles

Cited by

References

    1. Lewis K. Platforms for antibiotic discovery. Nat. Rev. Drug Discov. 2013;12:371–387. doi: 10.1038/nrd3975. - DOI - PubMed
    1. Provenzani A., Hospodar A.R., Meyer A.L., Leonardi Vinci D., Hwang E.Y., Butrus C.M., Polidori P. Multidrug-resistant Gram-negative organisms: A review of recently approved antibiotics and novel pipeline agents. Int. J. Clin. Pharm. 2020;42:1016–1025. doi: 10.1007/s11096-020-01089-y. - DOI - PubMed
    1. Martin-Loeches I., Dale G.E., Torres A. Murepavadin: A new antibiotic class in the pipeline. Expert Rev. Anti. Infect. Ther. 2018;16:259–268. doi: 10.1080/14787210.2018.1441024. - DOI - PubMed
    1. World Health Organization World Health Organization Releases Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. [(accessed on 24 May 2021)]; Available online: https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-E...
    1. Köhler C.D., Dobrindt U. What defines extraintestinal pathogenic Escherichia coli? Int. J. Med. Microbiol. 2011;301:642–647. doi: 10.1016/j.ijmm.2011.09.006. - DOI - PubMed

LinkOut - more resources